These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37846172)

  • 1. Apatinib potentiates the therapeutic effect of anti-PD-1 in locally advanced head and neck cancers.
    Liu S; Zhang L; Ye W; Zhou R; Gu Z; Shi C; Xu S; Li J; Zhang Z; Han Y
    Oral Dis; 2024 Jul; 30(5):2940-2951. PubMed ID: 37846172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
    Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
    Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.
    Lim SM; Kang SS; Kim DK; Lee SH; Synn CB; Baek S; Yang SM; Han YJ; Kim MH; Han H; Na K; Kim YT; Yun MR; Kim JH; Byeon Y; Kim YS; Lee JB; Hong MH; Curtin JC; Patel B; Bergiers I; Pyo KH; Cho BC
    Cancer Res Commun; 2024 Jul; 4(7):1748-1764. PubMed ID: 38916448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials.
    Liang L; Wen Y; Hu R; Wang L; Xia Y; Hu C; Qiao Y; Geng X; Chen T; Fei J; Hui K; Jiang X
    Cancer Immunol Immunother; 2019 Sep; 68(9):1467-1477. PubMed ID: 31451841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
    He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
    Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
    Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
    Cai X; Wei B; Li L; Chen X; Liu W; Cui J; Lin Y; Sun Y; Xu Q; Guo W; Gu Y
    Int Immunopharmacol; 2020 Nov; 88():106858. PubMed ID: 32795895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study.
    Xia H; Zhang H; Ruan Z; Zhang H; Sun L; Chen H; Zhou Y; Zhang L; Bian D; Zhu X; Zhang J; Sun F; Yu H; Song N; Liu X; Zhu Y; Zhang H; He W; Chen J; Yang J; Chen G; Xie S; Tang D; Zhang X; Duan L; Zhao D; Li Q; Zhang P; Jiang G
    Signal Transduct Target Ther; 2024 Jun; 9(1):145. PubMed ID: 38871690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
    Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
    J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
    Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
    Saito S; Kono M; Nguyen HCB; Egloff AM; Messier C; Lizotte P; Paweletz C; Adkins D; Uppaluri R
    Clin Cancer Res; 2024 May; 30(9):1934-1944. PubMed ID: 38372707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity enhances the response to neoadjuvant anti-PD1 therapy in oral tongue squamous cell carcinoma.
    Tan X; Li G; Deng H; Xiao G; Wang Y; Zhang C; Chen Y
    Cancer Med; 2024 Jun; 13(12):e7346. PubMed ID: 38923758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
    Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
    Front Immunol; 2021; 12():737076. PubMed ID: 34659228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
    Liu L; Liu Y; Gong L; Zhang M; Wu W
    Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.